Company Overview of Hydra Biosciences, Inc.
Hydra Biosciences, Inc., a biopharmaceutical company, engages in the identification and development of therapeutic agents that treat pain, inflammation, anxiety, renal, and pulmonary diseases. The company was founded in 2001 and is based in Cambridge, Massachusetts.
45 Moulton Street
Cambridge, MA 02138
Founded in 2001
Key Executives for Hydra Biosciences, Inc.
Chief Executive Officer, President and Director
Scientific Co-Founder and Member of Scientific Advisory Board - Cardiac Regeneration
Scientific Co-Founder and Member of Scientific Avisory Board - Cardiac Regeneration
Scientific Co-Founder, Chair of Scientific Advisory Board and Member of Pain Medical Advisory Board
Interim Chief Financial Officer
Compensation as of Fiscal Year 2015.
Hydra Biosciences, Inc. Key Developments
Hydra Biosciences Announces the Formation of a Pulmonary Medical Advisory Board
Aug 5 15
Hydra Biosciences announced the formation of a Pulmonary Medical Advisory Board. Three experts in pulmonary medicine, Dr. William Busse, Dr. Paul O’Byrne and Dr. Sven-Erik Dahlén, were appointed to the board. The three members of the advisory board are leaders in allergy and immunology, asthma and pulmonology: William W. Busse, M.D., is professor of Medicine at the University of Wisconsin Medical School, where he has taught since 1974 and has served as head of the Allergy and Clinical Immunology Division and Chair of Medicine. Paul O’Byrne, M.D., is the E. J. Moran Campbell Professor of Medicine and Chair of the Department of Medicine at the Michael G. DeGroote School of Medicine at McMaster University. He is also the executive director of the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare. Sven-Erik Dahlén, M.D., Ph.D., is a professor of experimental asthma and allergy research and the director of the Centre for Allergy Research at Karolinska Institutet in Stockholm. He has held many positions and appointments in pulmonary medicine, including serving as the Scientific Advisor for the Swedish Public Health Institute and on multiple boards at the Karolinska Institutet.
Hydra Biosciences Announces Executive Appointments to Newly Created Pain Medical Advisory Board
Jun 4 15
Hydra Biosciences announced newly formed pain medical advisory board (MAB) with the appointments of three leading physicians and scientists, Dr. Robert Dworkin, Dr. Roy Freeman and Dr. Nathaniel Katz. Dr. Paul Goldenheim, member of the Hydra Biosciences Board of Directors and Hydra founder, Dr. David Clapham, chair of the Hydra Scientific Advisory Board, also have seats on the MAB, which will provide clinical and scientific guidance as Hydra continues to develop HX-100, its clinical stage TRPA1 antagonist, in painful diabetic neuropathy. Robert Dworkin, Ph.D., is a professor of anesthesiology, neurology, oncology and psychiatry in the Center for Human Experimental Therapeutics, and director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry. Roy Freeman, M.D., is a professor of neurology at Harvard Medical School and director of the Center for Autonomic and Peripheral Nerve Disorders in the Department of Neurology at Beth Israel Deaconess Medical Center in Boston. Dr. Freeman also is chairman of the World Federation of Neurology research group on the autonomic nervous system. Nathaniel Katz, M.D.is a neurologist and pain management specialist with a distinguished career spanning Harvard Medical School, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Dr. Katz also served as Chair of the Advisory Committee, Anesthesia, Critical Care and Addiction Products Division for the FDA.
Hydra Biosciences, Inc. Presents at Boston CEO Conference, May-27-2015 02:00 PM
Apr 16 15
Hydra Biosciences, Inc. Presents at Boston CEO Conference, May-27-2015 02:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Russell H. Herndon, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 17, 2015